Corticotropin-releasing hormone (CRH) is believed to play a critical role in stress-induced synaptic formation and modification. In the current study, we explored the mechanisms underlying CRH modulation of synaptic formation in the hippocampus by using various models in vitro. In cultured hippocampal slices, CRH treatment decreased synapsin I and postsynaptic density protein 95 (PSD95) levels via CRH receptor type 1 (CRHR1). In isolated hippocampal neurons, however, it increased synapsin I-labeled presynaptic terminals and PSD95-labeled postsynaptic terminals via CRHR1. Interestingly, the inhibitory effect of CRH on synapsin I-labeled and PSD95-labeled terminals occurred in the model of neuron-glia cocultures. These effects were prevented by CRHR1 antagonist. Moreover, treatment of the neurons with the media of CRH-treated glia led to a decrease in synaptic terminal formation. The media collected from CRH-treated glial cells with CRHR1 knockdown did not show an inhibitory effect on synaptic terminals in hippocampal neurons. Unbiased cytokine array coupled with confirmatory enzyme-linked immunosorbent assay revealed that CRH suppressed C-X-C motif chemokine 5 (CXCL5) production in glia via CRHR1. Administration of CXCL5 reversed the inhibitory effects of CRH-treated glia culture media on synaptic formation. Our data suggest that CRH suppresses synapse formation through inhibition of CXCL5 secretion from glia in the hippocampus. Our study indicates that glia-neuron intercommunication is one of the mechanisms responsible for neuronal circuit remodeling during stress. (Endocrinology 159: 622-638, 2018) C orticotropin-releasing hormone (CRH), a 41-aminoacid neuropeptide, acts as a principal component of the hypothalamic-pituitary-adrenal axis (1). In addition to hypothalamus, where CRH was originally identified, CRH is widely expressed in the central nervous system, including the neocortex, basal ganglia, amygdala, and hippocampus (2, 3). Emerging evidence indicates that CRH is the key mediator in stress-related brain disorders and impaired learning and memory. These effects result primarily from neuroplasticity including neurogenesis, synaptic alternation, and formation (4-6). The effects of CRH on synapse formation and integrity vary between studies, in particular with variety in different brain regions. For instance, CRH increases spine and synapse formation in the cerebellum (7), whereas it mediates stress-induced rapid loss of apical dendritic spines in CA1 and CA3 pyramidal cells of the hippocampus (8, 9). In corticotropin-releasing hormone receptor type 1 (CRHR1) knockout mice, the absence of CRHR1 prevents the detrimental effects of chronic stress on dendritic arborization of CA3 neurons and spatial memory (5, 10). Moreover, the effects of CRH on synaptogenesis in cultured neurons conflict with those in organotypic culture of brain slices. CRH increases dendrite outgrowth in cultured hippocampal neurons (11); in contrast, it suppresses dendrite growth in cultured slices of the
C orticotropin-releasing hormone (CRH), a 41-aminoacid neuropeptide, acts as a principal component of the hypothalamic-pituitary-adrenal axis (1) . In addition to hypothalamus, where CRH was originally identified, CRH is widely expressed in the central nervous system, including the neocortex, basal ganglia, amygdala, and hippocampus (2, 3) . Emerging evidence indicates that CRH is the key mediator in stress-related brain disorders and impaired learning and memory. These effects result primarily from neuroplasticity including neurogenesis, synaptic alternation, and formation (4) (5) (6) . The effects of CRH on synapse formation and integrity vary between studies, in particular with variety in different brain regions. For instance, CRH increases spine and synapse formation in the cerebellum (7) , whereas it mediates stress-induced rapid loss of apical dendritic spines in CA1 and CA3 pyramidal cells of the hippocampus (8, 9) . In corticotropin-releasing hormone receptor type 1 (CRHR1) knockout mice, the absence of CRHR1 prevents the detrimental effects of chronic stress on dendritic arborization of CA3 neurons and spatial memory (5, 10) . Moreover, the effects of CRH on synaptogenesis in cultured neurons conflict with those in organotypic culture of brain slices. CRH increases dendrite outgrowth in cultured hippocampal neurons (11) ; in contrast, it suppresses dendrite growth in cultured slices of the hippocampus (12) . Thus, the mechanisms by which CRH modulates synapse formation remain largely unknown.
An increasing body of evidence has strongly suggested that glial cells play critical roles in the formation, stabilization, and elimination of synapses in both the peripheral and central nervous systems (13) (14) (15) . Such effects are mediated by soluble signals secreted by glia. A number of secreted factors of glia, such as thrombospondins, cholesterol with apolipoprotein E, glypican 4 and 6, transforming growth factor b, brain-derived neurotrophic factor (BDNF), and tumor necrosis factor a, have recently been identified to regulate various aspects of synapse formation (16) (17) (18) (19) (20) (21) . Interestingly, some studies have demonstrated that CRH can regulate secretion of a number of factors, such as tumor necrosis factor a and BDNF, in glial cells (19, 20) . We hypothesized that glia might be involved in CRH modulating synapse formation and modification. To test this hypothesis, we set up a series of experiments by using various models in vitro. Given that synapsin I links synaptic vesicles to cytoskeletal elements within the presynaptic terminal (22) (23) (24) and postsynaptic density protein 95 (PSD95) orients perpendicular to the postsynaptic membrane (25, 26) , we used synapsin I and PSD95 as presynaptic and postsynaptic markers, respectively. First, we compared the effects of CRH on presynaptic and postsynaptic related proteins, such as synapsin I and PSD95, in organotypic culture of hippocampal slices and synapsin I-and PSD95-labeled terminals formation in cultured hippocampal neurons. Second, we explored whether glia contributed to CRH modulation of synapse formation in the model of neuronglia cocultures and neuron cultures with glia-conditioned media (GCM), and subsequently we identified the key mediators produced by glia. Finally, we defined the signaling pathways responsible for CRH regulating cytokine release in glia.
Materials and Methods

Organotypic hippocampal slice culture
All animal protocols were approved by the Ethical Committee of Experimental Animals of Second Military Medical University, China. Protocols were designed to minimize the number of animals used and their suffering. Sprague-Dawley rats were obtained from Sino-British SIPPR/BK Laboratory Animal Ltd, Shanghai, China. Hippocampal slice cultures were prepared from male rats on postnatal (P) days P2 and P3. In each independent culture, six to eight male newborn rats from same litter were used. The cultures were followed by the method described by Bender et al. (27, 28) . Briefly, after decapitation rat brains were removed and placed in ice-cold oxygenated lowsodium artificial cerebral spinal fluid (containing 248 mM sucrose, 4 mM KCl, 1.25 mM NaH 2 PO 4 , 26.2 mM NaHCO 3 , 1 mM CaCl 2 , 5 mM MgCl 2 , and 10 mM glucose) and then carefully placed on the platform of a tissue chopper and sliced perpendicular to their longitudinal axes with a vibrating microtome (NVSLM1; World Precision Instruments Inc., Sarasota, FL), with 400 mm thickness of each slice. Slices were transferred to Millicell CM membrane inserts (Millipore, Bedford, MA) in six-well culture plates. Each well contained 1.2 mL of prewarmed Dulbecco's modified Eagle medium (DMEM) (Invitrogen Corp., Carlsbad, CA) containing 20% horse serum (Invitrogen), 10.5 mM glucose, 12.5 mM HEPES, and 55 mM NaHCO 3 (pH 7.3 to 7.4). The slices were incubated in a humidified, 5% CO 2 atmosphere at 37°C overnight, and followed by treatments with increasing concentrations (10 212 to 10 28 M) of CRH (Sigma-Aldrich, St. Louis, MO) in the absence or presence of CRHR1 antagonist antalarmin (SigmaAldrich) and CRHR2 antagonist astressin2B (Sigma-Aldrich) for 48 hours. The dosages of CRH were selected according to the literature (29) and our previous studies (11) . The media and slices were collected for subsequent analysis. CRH and astressin2B were dissolved in phosphate-buffered saline (PBS) and stored in 0.1-mM stock at 280°C, and antalarmin was dissolved in dimethyl sulfoxide to achieve a stock of 10 mM, then diluted by culture medium to achieve the final concentration of dimethyl sulfoxide ,0.01%.
Hippocampal neuron culture
Primary hippocampal neurons were cultured as described previously (30) . Briefly, hippocampi were dissected from P1 male Sprague-Dawley rats (six to eight male newborn rats from same litter were used in each independent culture) in ice-cold dissection solution containing 136 mM NaCl, 5.4 mM KCl, 0.2 mM Na 2 HPO 4 , 2 mM KH 2 PO 4 , 16.7 mM glucose, 20.8 mM sucrose, 10 mM HEPES, and 0.0012% phenol red, pH 7.4, and then incubated with 0.125% trypsin (Invitrogen) at 37°C for 15 minutes. Cell suspensions were obtained by mechanical dissociation in DMEM supplemented with 10% heatinactivated fetal bovine serum (FBS) (Invitrogen) and 10% horse serum. Cells were plated at a density of 1 3 10 5 cells/cm 2 on poly-L-lysine (Sigma-Aldrich) coated coverslips and six-well plates. Cultures were then maintained in 5% CO 2 at 37°C in DMEM containing 10% heat-inactivated FBS and 10% horse serum overnight. Cytosine arabinoside (1 mM) was added into cultures 24 hours after plating to block the proliferation of glial cells, and the culture media were changed to serum-free B27/ neurobasal medium (Invitrogen). Half of the medium was replaced with fresh medium every 3 days. After 7-day culture, cells were treated with various concentrations of CRH in the absence or presence of antalarmin and astressin2B for 48 hours. In some cases, cells were incubated with GCM or GCM plus recombinant C-X-C motif chemokine 5 (CXCL5) (rLIX, R&D Systems, Minneapolis, MN), antirat CXCL5 antibody (R&D Systems), or CXCR2 antagonist SB265610 (Sigma-Aldrich) for 48 hours.
Culture of glial cells
Cultures of mixed glia were established according to the method described previously (19, 31) . Briefly, hippocampi were prepared from P2 to P3 male Sprague-Dawley rats (four to six male newborn rats from same litter were used in each independent culture) in ice-cold dissection solution and were dissociated by trypsin (0.125%) at 37°C for 15 minutes. After mechanical dissociation in DMEM supplemented with 15% heat-inactivated FBS, single-cell suspensions were obtained and then plated in 75-cm 2 culture flasks and maintained at 37°C in a 5% CO 2 humidified incubator. Half of the medium was replaced by fresh medium every 3 days for a total of 12 to 14 days. Mixed glial cells in flasks were trypsinized, counted, spun down, and resuspended in culture media and replaced onto poly-L-lysine-coated coverslips, 12-well plates, and transwell inserts. After 4-day culture, the cultures were administrated with CRH, antalarmin, and astressin2B for the indicated time. In some cases, cells were treated with the aforementioned reagents for 48 hours, and then media were harvested and spun down to remove cell debris. These media served as GCM to be used for treatment of isolated neurons.
To purify astrocytes from mixed glial cells, cells were allowed to grow for 14 to 21 days. After reaching confluence, cells were shaken at 250 rpm for 18 to 20 hours in DMEM containing 10% FBS on a gyratory shaker at 37°C to remove neurons and other cell types. The cells were then plated onto poly-L-lysine-coated 12-well and 6-well plates and maintained in DMEM containing 10% FBS at 37°C and 5% CO 2 . Purified astrocytes were treated with various concentrations of CRH in combination with antalarmin, astressin2B, H89, Gö6976, U73122, chelerythrine, forskolin, SQ22536, 8-Br-cAMP, and pertussis toxin (PTX) for the indicated time. All the aforementioned reagents were purchased from Sigma-Aldrich.
The purity of astrocytes was assessed by imunocytochemistry with anti-GFAP antibody. It was shown that .95% of such cells GFAP positive (Supplemental Fig. 1 ).
Glia-neuron coculture
Glia-neuron coculture was performed in a six-well transwell chamber system with a 4-mm pore size (Corning, Corning, NY), which permitted cell contact-independent communication via diffusible soluble factors only. Freshly isolated mixed glial cells were plated in transwell inserts at 5 3 10 4 cells per insert. The inserts then were placed on top of each well of the six-well plates, where neurons were cultured and maintained throughout the culture time until subsequent experiments were performed. These clusters were calculated in individual neurons with easily distinguishable processes, as described in a previous study (32) . The intensity of synapsin I, PSD95, and synapsin I-PSD95 overlapping positive clusters per region of interest (ROI) was taken along the same neuronal branch. At least five visual fields were acquired in each independent culture. The mean values of the positive clusters or costained contacts in each culture were determined.
Immunofluorescence analysis
Western blot analysis
Cells were scraped off the plates in the presence of lysis buffer, which consists of 60 mM Tris-HCl, 2% sodium dodecyl sulfate (SDS), 10% sucrose, 2 mM phenylmethylsulfonyl fluoride (Merck, Darmstadt, Germany), 1 mM sodium orthovanadate (Sigma-Aldrich), and 10 g/mL aprotinin (Bayer, Leverkusen, Germany). Hippocampal tissues were homogenized in the presence of the aforementioned lysis buffer. The lysates were quickly sonicated, boiled for 5 minutes at 95°C, and centrifuged at 12,000g for 5 minutes at 4°C. Then, the supernatants were collected and the protein concentration in supernatant was assayed with a modified Bradford assay. The samples were diluted in sample buffer [250 mM Tris-HCl (pH 6.8), containing 4% SDS, 10% glycerol, 2% b-mercaptoethanol, and 0.002% bromophenol blue] and boiled for another 5 minutes. Aliquots of the samples were separated by 10% SDS polyacrylamide gel electrophoresis and subsequently transferred to nitrocellulose membranes by electroblotting. The membrane was blocked in 5% skim milk powder in 0.1% Trisbuffered saline/Tween 20 at room temperature for 2 hours, and then was incubated with antibodies against synapsin I, PSD95, CRHR1 (Bioworld Technology Inc.), phospholipase C (PLC)-b 3 (sc133231; Santa Cruz), and phosphorylated PLC-b 3 (Ser 537) (2481; Cell Signaling Technology, Boston, MA) at a dilution of 1:1000 overnight at 4°C. After three washes with 0.1% Trisbuffered saline/Tween 20, the membranes were incubated with a secondary horseradish peroxidase conjugated antibody (Santa Cruz) for 1 hour at room temperature. Immunoreactive proteins were detected with and enhanced chemiluminescence Western blot detection system (Santa Cruz) and visualized with a Sygene Bio Image system (Synoptics Ltd., UK). To control sampling errors, the ratio of band intensities to b-actin (A5441; Sigma-Aldrich) was obtained to quantify the relative protein expression level.
Cell viability assay
To examine whether the reagents have detrimental effects on neurons, viability was tested. The cells were incubated with 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (Sigma-Aldrich) at 0.5 mg/mL for 2 hours after treatment with various reagents. Then, the cells were lysed with dimethyl sulfoxide in Sorensen glycine buffer and the formazan crystals solubilized. Absorbance was read at 570 nm with a spectrophotometric microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA).
Cytokine array and enzyme-linked immunosorbent assay
Glial cells were treated with CRH (10 28 M) in the presence or absence of antalarmin (10 27 M) for 48 hours, and the media were collected. The media of three independent cultures were pooled together for following cytokine array. The output of total of 34 cytokines in media was evaluated with a rat cytokine antibody array G series (Ray Biotech Inc., Norcross, GA) according to the manufacturer's instructions.
The concentration of CXCL5 (i.e., LIX) in media of cell cultures and brain slices was determined with a RayBio Rat LIX enzyme-linked immunosorbent assay (ELISA) kit (Ray Biotech Inc.) according to the manufacturer's instructions. The LIX kit shows no cross-reactivity with other cytokines including CINC-2, CINC-3, CNTF, fractalkine, IL-1a, IL-1b, IL-4, IL-6, IL-10, GM-CSF, leptin, CCL-2, b-NGF, TIMP-1, VEGF, TNF-a, INF-g, and MIP-3a in rats. The sensitivity of the LIX assay was ,15 pg/mL. Intra-assay variation is ,10%, and interassay variation is ,12%.
Small interfering RNA transfection
The sequence-specific small interfering RNA (siRNA) targeting rat CRHR1 was designed and synthesized by GenePharma Corporation (Shanghai, China). The siRNA targeting CRHR1 (sense 5 0 -CCGCCUACAAUUACUUCCATT-3 0 ; antisense 5 0 -UGGAA-GUAAUUGUAGGCGGTT-3 0 ) was used for knockdown of the CRHR1 gene in mixed glia in vitro. The following siRNA (sense 5 0 -UUCUCCGAACGUGUCACGUTT-3 0 ; antisense 5 0 -ACGU-GACACGUUCGGAGAATT-3 0 ), without homology to any known rat messenger RNA sequences in the NCBI RefSeq database, was used as a negative control. The cultured glial cells were transfected with siRNA-CRHR1 and negative control siRNA with siPORT™ NeoFX™ transfection agent (Ambion, Austin, TX).
Determination of activated Gi protein
The level of active GTP-bound Gi protein was determined with a commercial Gi activation assay kit (NewEast Biosciences, Malvern, PA). Cultured astrocytes were treated with increasing concentrations of CRH (10 212 to 10 28 M) in the absence and presence of CRHR1 antagonist antalarmin (10 27 M) for 5 minutes and then scraped off the plate in the presence of lysis buffer supplied with the kit. The cell lysate was centrifuged for 10 seconds at 12,000g, and then all supernatants were immunoprecipitated with antiactive Gi monoclonal antibody, and protein A/G agarose beads were added to cell lysates. After incubation at 4°C for 1 hour, the beads were pelleted and resuspended three times (10 minutes each) in lysis buffer. Then the samples were centrifuged for 10 seconds at 12,000g, and the supernatant containing active GTP-bound Gi protein was collected. Samples were analyzed by Western blot with anti-Gi monoclonal antibody. To control sampling errors, the total Gi protein was determined by Western blot analysis.
cAMP assay
Astrocytes were treated with increasing concentrations of various reagents for 10 minutes, then scraped off the plate in the presence of 50 mM sodium acetate (pH 4.75). In some cases, the cells were transfected with CRHR1 siRNA and then treated with CRH (10 28 M) for 10 minutes. Lysates were boiled at 95°C for 10 minutes and then quickly sonicated in an ice bath. The supernatants were collected by centrifugation and used for cAMP assay according to the protocol of a commercial 125 I RIA kit (Huaying Biotechnology Research Institute, Peking, China). The sensitivity of cAMP assay was ,0.8 pmol/mL. Intra-assay and interassay variations are , 8 .9%. The kit shows no crossreactivity with other small molecules in rats.
IP 3 assay
Astrocytes were treated with increasing concentrations of various reagents for 10 minutes, then scraped off the plate in the presence of 50 mM sodium acetate (pH 4.75). In some cases, the cells were transfected with CRHR1 siRNA and then treated with CRH (10 28 M) for 10 minutes. After the cells were frozen three times, the supernatants were collected by centrifugation (3000g for 20 minutes). IP 3 content in supernatants was determined with the IP 3 ELISA kits (R&D Systems, Minneapolis, MN). The sensitivity of the IP 3 assay was ,2 pg/mL. There is no cross-reactivity with other small molecules in this kit. The interassay and intra-assay variations are ,10%. To avoid the errors that would occur in different assays, IP 3 contents were determined by bulk assay of the cells with various treatments.
Statistical analysis
The n value represents the numbers of independent cultures. All data are presented as mean 6 standard error of the mean (SEM). After confirmation of normal distribution, one-way analysis of variance (ANOVA) followed by least significant difference (LSD)-t test or factorial design ANOVA was used to appropriately assess the difference in all variables. SPSS software version 16.0 was used. P , 0.05 was considered statistically significant.
Results
CRH suppresses presynaptic and postsynaptic related protein levels in hippocampal slices
Treatment Because the major difference between isolated neurons and hippocampal slices is the cell component (i.e., glia), we set up glia-neuron cocultures to mimic the cell component of brain slices. In this model, we found that CRH (10 28 M) treatment for 48 hours led to an inhibition of synapse formation. The numbers of synapsin I-labeled terminals, PSD95-labeled terminals, and colocalized complexes around the neuronal processes were significantly suppressed by CRH treatment compared with vehicle control [ Fig. 3(a) Cell viability assessment showed that the neuron viability remained unaffected after CRH incubation (Supplemental Fig. 2 ).
GCM of CRH-treated glia exhibits an inhibitory effect on synapse formation
We then explored whether soluble and diffusible factors secreted by glial cells upon CRH treatment would be responsible for synapse formation. It was shown that the numbers of synapsin I-labeled clusters and PSD95-positive clusters were significantly decreased when the hippocampal neurons were incubated with the GCM of CRH (10 Western blot analysis showed that synapsin I and PSD95 protein levels in hippocampal neurons were decreased by the treatment of GCM collected from glia treated with various concentrations of CRH [ Fig. 4 The GCM of the glia treated with CRH plus astressin2B showed suppression on both synapsin I and PSD95 expression level [ Fig. 4 (e) and 4(f), synapsin I, F(5, 18) = 30.33, P , 0.001; GCM of glia treated with CRH plus astressin2B vs vehicle GCM, LSD-t(18) = 27.88, P , 0.001; PSD95: F(5, 18) = 65.56, P , 0.001; GCM of glia treated with CRH plus astressin2B vs vehicle GCM, LSD-t(18) = 211.81, P , 0.001].
Sequence-specific siRNA targeting CRHR1 was used to further confirm the role of CRHR1 in glial cells in CRH-induced suppression of synapse formation. CRHR1 siRNA transfection led to 63.3% 6 4.8% decrease in CRHR1 expression in glial cells (Supplemental Fig. 3 ). The GCM was collected from glial cells of CRHR1 knockdown with CRH (10 28 M) treatment of 24 hours. Treatment of hippocampal neurons with the above GCM did not affect the number of synapsin Ilabeled and PSD95-labeled terminals. However, the GCM, which was harvested from CRH-treated glial Table 1 ].
To confirm the effect of CRH on CXCL5 output, we measured CXCL5 levels in the culture media of the neurons treated with increasing concentrations of CRH. It was showed that CRH dose-dependently decreased CXCL5 output. This effect was prevented by CRHR1 antagonist antalarmin [ Fig. 6(c) ; F(7, 24) = 20.20, P , 0.001; CRH plus antalarmin vs CRH: LSD-t(24) = 7.11, P , 0.001] and CRHR1 siRNA [ Fig. 6(d) , interaction F(1, 12) = 20.14, P , 0.001]. We also found that CRH treatment caused a decrease in CXCL5 content in the cultured hippocampal slice, which was blocked by antalarmin [ Fig. 6(e) , F(7, 24) = 25.30, P , 0.001; CRH vs vehicle, LSD-t(24) = 28.38, P , 0.001; CRH plus antalarmin vs CRH, LSD-t(24) = 8.69, P , 0.001].
We subsequently examined whether CXCL5 mediates CRH modulation of synapse formation in cultured hippocampal neurons. At first, we found that administering CXCR2 antagonist SB265610 to the neurons incubated with vehicle GCM reduced synapsin I-labeled and PSD95-labeled terminals and clusters [ Fig. 7 CRH inhibits CXCL5 production in astrocytes through multiple signaling pathways Astrocytes, microglia, and oligodendrocytes are main types of glial cells in rodents. We showed that astrocytes are the predominant cell type in glia isolated from the hippocampus (Supplemental Fig. 1 ). We therefore investigated the signaling pathways responsible for CRH suppressing CXCL5 secretion in cultured astrocytes. CRH (10 212 to 10 
Discussion
This study demonstrated that CRH acts on glia to inhibit CXCL5 secretion, subsequently leading to suppression of synapse formation in the hippocampus. These data may indicate that glia-neuron intercommunication is one of the mechanisms responsible for neuronal circuits remodeling during stress.
The hippocampus, one of the most plastic regions in brain, is highly sensitive to stress (33) (34) (35) . Many studies have demonstrated that stress induces structural changes of synapses in the hippocampus, with concomitant changes in cognitive function and affective behavior (4-6, 36, 37) . As mentioned, CRH is one of the key factors involved in stress-induced synaptic abnormalities, particularly synapse-bearing dendritic spines in the hippocampus (7) (8) (9) (10) 38) . CRH is synthesized mainly by pyramidal cell layer interneurons and released during stress (39, 40) . Blockage of CRHR1 prevented stress-induced spine loss and dendritic atrophy induced by stress in the hippocampus (39, 41) . Liao et al. (42) recently reported that CRHR1 antagonist attenuated downregulation of synapse-related proteins induced by stress in the hippocampus. In addition, an in vitro study by Chen et al. (43) showed that CRH suppresses dendritic spine density in hippocampal slices. Consistently, the current study showed that CRH suppressed synaptic formation in the hippocampus via CRHR1. The molecular mechanisms by which CRH modulates synapse formation in the hippocampus remain largely unknown. Emerging evidence has indicated that glial cells, such as astrocytes, play critical roles in neuronal differentiation and circuitry formation in the last decade (44, 45) . In the hippocampus, about 64% of synapses are contacted by perisynaptic astrocytes at the synaptic cleft (46, 47) . The intricate arborization and ramifications of astrocytes allow them to tightly enwrap the synaptic terminal to modulate synaptic processes and plasticity (46, 48) . Previous studies have implied that glia might play a role in CRH modulation of synapse formation because it has been shown that CRH displays differential effects on synaptic formation in the model of cultured neurons and brain slices (11, 12) . Interestingly, the current study also demonstrated the opposite effects of Fig. 8(c) and 8(h) were statistically analyzed by factorial design ANOVA, whereas the data for other figures were analyzed by one-way ANOVA followed by LSD-t test. *P , 0.05; **P , 0.01 vs control; # P , 0.05; ## P , 0.01 vs CRH. Anta, antalarmin.
CRH on synapse formation in isolated hippocampal neurons and organotypic hippocampal slices. Moreover, we have shown that similar effects of CRH on synapticrelated protein expression and synaptic formation occurred in hippocampal slices and glia-neuron cocultures. Knockdown of CRHR1 in glial cells prevented CRH suppression of synapse formation in the model of glianeuron cocultures. These data provided the strong evidence that glial cells played a key role in CRH suppression of synaptic formation in the hippocampus. The glial cells regulate synapse remodeling and plasticity through contact molecules and soluble secreted factors. A number of soluble factors secreted by glia have been identified to be involved in synapse formation, such as thrombospondins, transforming growth factor -b, and BDNF (16, 19, 20) . In the current study, we demonstrated that a chemokine, CXCL5 (LIX), played a critical role in maintenance of synaptic formation in the hippocampus, as evidenced by blockage of CXCL5 leading to decreased synapse formation in glianeuron cocultures. A number of studies have demonstrated that glia can synthesize and secrete various cytokines, such as IL-1, IL-6, and IL-10, and chemokines including CCL2, CCL3, CCL4, CXCL12, and CXCL14 (49) (50) (51) (52) (53) (54) (55) (56) (57) . These cytokines and chemokines are involved in neurogenesis, neuronal survival, synaptic transmission, and synaptic plasticity. For instance, IL-10 promotes synapse formation in cultured cortical neurons (52) , whereas chemokines CCL2, CCL3, and CXCL14 have been shown to modulate synaptic transmission (53, 54, 57) .
In the current study, we confirmed that CRHR1 was expressed in hippocampal glia in rats. Furthermore, we demonstrated that CRHR1 activation led to inhibition of AC/cAMP signaling and activation of PLC/PKC signaling in astrocytes, and these signaling pathways mediated CRH inhibition of CXCL5 secretion. CRH receptors, particularly CRHR1, can couple to multiple G proteins with subsequent activation of multiple signaling pathways in various tissues (58) . Our previous studies have shown that CRHR1 can couple to Gs and Gq proteins in hippocampal neurons of rats (59, 60) ; in contrast, it couples to Gi, Gs, and Gq in human myometrium (61 Nevertheless, we have demonstrated CRHR1 activation of a Gi/AC/cAMP signaling pathway by the following evidence: CRHR1 activation leads to activation of Gi protein and a decrease in cAMP production, and blockage of Gi activation prevents CRHR1 inhibition of CXCL5 secretion. As mentioned, CRH can be secreted from interneurons in the hippocampus during stress (40, 41), which contributes to spine loss during stress (9). We Figure 9 . Scheme illustrating CRH regulation of synapse formation in the hippocampus. CXCL5 secreted by glial cells plays a critical role in synaptic terminal formation of pyramidal neurons in the hippocampus. CRH can be released from interneurons by various stimuli (such as stress) in the hippocampus. CRH then acts on CRHR1 in glia to suppress CXCL5 secretion from glia, resulting in a decrease in synapses in pyramidal neurons. AC, adenylyl cyclase; PKA, protein kinase A. therefore propose that, during stress, increased CRH secretion inhibits CXCL5 secretion by glia via CRHR1, leading to suppression of synapse formation in hippocampal neurons (Fig. 9) . Our study may indicate that glia-neuron communication is critical for remodeling of synapse circuits in the brain during stress.
